This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 17.72% and 8.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Gears for a Hectic Earnings Week
by Zacks Equity Research
Wall Street Gears for a Hectic Earnings Week.
Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.
Will Central Banks Start to Care About Fundamentals?
by John Blank
Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.
Markets Up to Start Another Busy Week
by Mark Vickery
With Q1 earnings season continuing to unfold favorably (for the most part), investors look to enjoy a healthy Q2, as well.
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, which has been developed in partnership with Pfizer.
3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.
AstraZeneca (AZN) Q1 Earnings Top, COVID-19 Vaccine Adds $275M
by Zacks Equity Research
AstraZeneca (AZN) surpasses first-quarter estimates on both counts. Stock up in pre-market.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Glaxo's (GSK) Q1 Earnings In Line, Sales Hit by COVID-19
by Zacks Equity Research
Glaxo's (GSK) revenues get hurt by disruption related to COVID-19 pandemic. However, robust growth in respiratory, immuno-inflammation and cancer drugs partially offset the decline.
Bristol-Myers (BMY) Misses on Q1 Earnings, Opdivo Sales Decline
by Zacks Equity Research
Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.
Will Pfizer (PFE) Deliver a Beat This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.
Healthcare ETFs on Radar As Q1 Earnings Unfold
by Sweta Killa
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $38.68, marking a +0.05% move from the previous day.
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.
Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate
by Zacks Equity Research
Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.
J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe
by Zacks Equity Research
J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).
Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe
by Zacks Equity Research
Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.
Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU
by Zacks Equity Research
The European Commission exercises its option to purchase an additional 100 million doses of Pfizer (PFE)/ BioNTech's COVID-19 vaccine, Comirnaty, for EU member states.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $38.93, marking a +0.93% move from the previous day.
The Zacks Analyst Blog Highlights: UnitedHealth, Pfizer, Accenture, Wells Fargo and Uber
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Pfizer, Accenture, Wells Fargo and Uber
Top Research Reports for UnitedHealth, Pfizer & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Pfizer (PFE), and Accenture (ACN).
Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development
by Kinjel Shah
FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.
Aon (AON) Launches Cargo Insurance Solution, Boosts Portfolio
by Zacks Equity Research
Aon (AON) unveils a cargo insurance solution for offering financial and supply chain protection, thereby, ensuring large-scale distribution of COVID-19 vaccines worldwide.